| Diabetes Mellitus, Non-Insulin-Dependent
Brenzavvy vs Invokamet
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Brenzavvy vs Invokamet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInvokamet has a higher rate of injection site reactions vs Brenzavvy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Invokamet but not Brenzavvy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brenzavvy
Invokamet
At A Glance
Oral
Daily
SGLT2 inhibitor
Oral
Once or twice daily
SGLT2 inhibitor + biguanide
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetic Nephropathy
Dosing
Diabetes Mellitus, Non-Insulin-Dependent 20 mg orally once daily in the morning, with or without food; do not crush or chew the tablet; withhold for at least 3 days prior to major surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent INVOKAMET: One tablet orally twice daily with meals, starting at canagliflozin 100 mg and metformin HCl 1,000 mg total daily dose. INVOKAMET XR: Two tablets orally once daily with morning meal, swallow whole. Maximum: canagliflozin 300 mg and metformin HCl 2,000 mg total daily. Not recommended if eGFR <45 mL/min/1.73 m2. Dose adjust for renal impairment: eGFR 45-60, max canagliflozin 100 mg daily; eGFR 30-45, assess benefit/risk, max canagliflozin 100 mg daily.
Diabetic Nephropathy Canagliflozin 100 mg orally once daily as a component of INVOKAMET or INVOKAMET XR. Dose adjust based on eGFR. Contraindicated if eGFR <30 mL/min/1.73 m2.
Contraindications
- Hypersensitivity to bexagliflozin or any excipient in BRENZAVVY
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Serious hypersensitivity reaction to canagliflozin or metformin HCl, such as anaphylaxis or angioedema
Adverse Reactions
Most common (>=2%) Increased urination, urinary tract infection, female genital mycotic infections, thirst, vaginal pruritus, male genital mycotic infection, hypoglycemia
Serious Diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, sepsis, fractures
Most common (>=2%) Urinary tract infections, increased urination, thirst, constipation, nausea, female genital mycotic infections, vulvovaginal pruritus, male genital mycotic infections
Serious Lactic acidosis, diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis, pyelonephritis, hypoglycemia with insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, bone fracture
Postmarketing Ketoacidosis, acute kidney injury, anaphylaxis, angioedema, urosepsis and pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), cholestatic hepatocellular and mixed hepatocellular liver injury
Pharmacology
Bexagliflozin is an SGLT2 inhibitor that blocks renal reabsorption of filtered glucose in the proximal tubule, lowering the renal threshold for glucose and increasing urinary glucose excretion to reduce blood glucose in adults with type 2 diabetes mellitus.
Canagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, lowers the renal threshold for glucose, and increases urinary glucose excretion, thereby lowering plasma glucose. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brenzavvy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Invokamet
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Brenzavvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Invokamet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Brenzavvy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Invokamet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brenzavvy.
No savings programs available for Invokamet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrenzavvyView full Brenzavvy profile
InvokametView full Invokamet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.